



CHALMERS
UNIVERSITY OF TECHNOLOGY

UBB+1 reduces amyloid-beta cytotoxicity by activation of autophagy in yeast

Downloaded from: <https://research.chalmers.se>, 2024-04-25 09:07 UTC

Citation for the original published paper (version of record):

Chen, X., Muñoz Arellano, A., Petranovic Nielsen, D. (2021). UBB+1 reduces amyloid-beta cytotoxicity by activation of autophagy in yeast. *Aging*, 13(21): 23953-23980.
<http://dx.doi.org/10.18632/aging.203681>

N.B. When citing this work, cite the original published paper.

UBB⁺¹ reduces amyloid- β cytotoxicity by activation of autophagy in yeast

Xin Chen^{1,2,*}, Ana Joyce Muñoz-Arellano^{1,*}, Dina Petranovic^{1,2}

¹Division of Systems and Synthetic Biology, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden

²Novo Nordisk Foundation Center for Biosustainability, Chalmers University of Technology, Gothenburg, Sweden

*Equal contribution

Correspondence to: Dina Petranovic; **email:** dina.petranovic@chalmers.se

Keywords: UBB⁺¹, autophagy, amyloid- β , Alzheimer's disease, yeast

Received: March 25, 2020

Accepted: July 2, 2021

Published: November 9, 2021

Copyright: © 2021 Chen et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

UBB⁺¹ is a mutated version of ubiquitin B peptide caused by a transcriptional frameshift due to the RNA polymerase II “slippage”. The accumulation of UBB⁺¹ has been linked to ubiquitin-proteasome system (UPS) dysfunction and neurodegeneration. Alzheimer's disease (AD) is defined as a progressive neurodegeneration and aggregation of amyloid- β peptides (A β) is a prominent neuropathological feature of AD. In our previous study, we found that yeast cells expressing UBB⁺¹ at lower level display an increased resistance to cellular stresses under conditions of chronological aging. In order to examine the molecular mechanisms behind, here we performed genome-wide transcriptional analyses and molecular/cellular biology assays. We found that low UBB⁺¹ expression activated the autophagy pathway, increased vacuolar activity, and promoted transport of autophagic marker ATG8p into vacuole. Furthermore, we introduced low UBB⁺¹ expression to our humanized yeast AD models, that constitutively express A β 42 and A β 40 peptide, respectively. The co-expression of UBB⁺¹ with A β 42 or A β 40 peptide led to reduced intracellular A β levels, ameliorated viability, and increased chronological life span. In an autophagy deficient background strain (*atg1 Δ*), intracellular A β levels were not affected by UBB⁺¹ expression. Our findings offer insights for reducing intracellular A β toxicity via autophagy-dependent cellular pathways under low level of UBB⁺¹ expression.

INTRODUCTION

Proteins are frequently misfolded during the lifetime of a cell, as a consequence of stochastic fluctuations of the structures, genomic mutations, oxidation or other different stress conditions [1]. Misfolded proteins often tend to aggregate due to the exposure of hydrophobic amino acid residues and unstructured polypeptide backbones, which are shielded in a native conformation [2]. Accumulation of misfolded proteins within cellular compartments or tissues is emerging as a major contributor or even a causative agent in human diseases which are called “conformational diseases” [3]. These include a diverse array of pathologies such as lysosomal

storage diseases [4], cystic fibrosis [5] and many neurodegenerative disorders [6, 7]. To minimize the detrimental effects that misfolded and aggregated proteins impose, cells have evolved efficient protein quality control (PQC) systems to maintain proteostasis, which consist of the ubiquitin-proteasome system (UPS), chaperone mediated autophagy (CMA) and autophagy [8].

UPS is the major selective proteolytic system in eukaryotic cells, which degrades short-lived regulatory proteins and soluble misfolded proteins [9]. The conjugation of a polyubiquitin chain to target proteins is an essential step for their degradation by the 26S

proteasome. Increasing evidences show that impaired and/or decreased function of the UPS is associated with many neurodegenerative diseases including Alzheimer's disease (AD) [10], Parkinson's disease (PD) and Huntington's disease (HD) [11]. In addition to disease-causing proteins (e.g., amyloid β , alpha-synuclein, or Huntingtin), there are often disruptions in the Ubiquitin B gene (UBB) and mRNA transcripts, as well as polyubiquitin depositions within aggregates made of disease-specific proteins. UBB⁺¹ is generated from a dinucleotide loss in the transcript due to RNA polymerase "slippage" during the transcription of the UBB gene, a process termed "molecular misreading". The hotspots for molecular misreading are near short repeat sequence, such as the GAGAG motif [12]. The result of misreading is a frameshift near 3' end of UBB mRNA transcript resulting in UBB⁺¹, a UBB peptide variant with additional 20 amino acids at the C-terminus. Unlike the UBB, UBB⁺¹ fails to ligate protein substrates or join polyubiquitin chains due to the absence of the C-terminal glycine residue, but like any other damaged protein recognized by the UPS system, it is readily ubiquitinated and degraded [13, 14].

AD is the most common form of neurodegeneration in aging population [15]. The accumulation of amyloid- β (A β) plaques in the brain is one of principal hallmarks of AD, which is thought to trigger a cascade of pathogenic processes [16]. Accumulation of UBB⁺¹ is a cellular hallmark of sporadic and autosomal AD cases, suggesting its pathological contribution [17, 18]. The presence of UBB⁺¹ has been proposed as an endogenous reporter for decreased UPS activity [19]. Previous studies showed that UBB⁺¹ acts as a ubiquitin-fusion-degradation substrate for the proteasome and its properties shift from substrate to inhibitor, in a dose-dependent manner [14, 20]. Low levels of UBB⁺¹ can be ubiquitinated and efficiently degraded by the UPS, whereas at high levels, the UPS fails to degrade UBB⁺¹ and the accumulation of UBB⁺¹ further induces functional impairment of the UPS. Prolonged expression of high levels of UBB⁺¹ affects mitochondrial dynamics and triggers neuronal cell death [21, 22]. Despite the UBB⁺¹-induced UPS dysfunction, in some cases UBB⁺¹ expression is protective by the induction of heat-shock proteins, which promote cellular resistance to oxidative stress [23, 24]. UBB⁺¹ expression reduces the A β plaque load in APPS1 mice during aging through restoration of PS1-NTF expression and γ -secretase activity [25].

Although the impact of UBB⁺¹ has been studied in different *in vivo* model systems, the precise role of UBB⁺¹ in UPS dysfunction and its importance during AD progression remains ambiguous. The yeast *Saccharomyces cerevisiae* is a powerful eukaryotic

model often used to study misfolded proteins and their implication in human pathologies due to the strong conservation of PQC systems between yeast and human cells [26]. To exploit the effects of UBB⁺¹ expression on proteasome function and cellular viability, we recently developed two yeast models using constitutive expression of the human UBB⁺¹, expressed at high and low levels [27]. We found that at low expression level, UBB⁺¹ enhances cellular resistance to misfolded proteins and oxidative stress during chronological aging, and prolongs chronological life span (CLS), which measures the survival time of nondividing cells [27]. A β 42 and A β 40 are two major isoforms of A β associated with AD. A β 40 is found in higher quantities in the affected brain tissue, but A β 42 is more hydrophobic and more prone to aggregation. To mimic the chronic cytotoxicity of A β isoforms accumulation in AD progression, we have developed two humanized yeast AD models with A β 42 and A β 40 expression, respectively [28, 29]. These models have been used as a platform for synthetic genetic array (SGA) to screen for modulators of A β 42 toxicity [30].

Here we take advantage of our low UBB⁺¹ expression strain (hereafter referred to as L-UBB⁺¹ strain) to investigate the underlying mechanisms that protect cells from stresses that we have previously identified [27] by using the genome-wide transcriptional analyses, followed by several molecular and cell biology assays. Transcriptome analyses helped to generate the hypotheses which were tested, which then led us to that low UBB⁺¹ expression activated the autophagy pathway, which then reduced intracellular A β levels and alleviated its cellular toxicity.

RESULTS

Low expression of human UBB⁺¹ significantly modifies the transcription of thousands of genes

We have previously shown that at low expression levels, UBB⁺¹ can extend CLS and increase cellular tolerance to misfolded proteins in yeast [27]. To investigate the mechanisms behind the observed phenotypes, we further performed a genome-wide transcriptional study and compared the gene expression between the control strain (carrying an empty vector) and the L-UBB⁺¹ strain, during the exponential growth phase (EX) and stationary phase (D6, i.e., 6 days after carbon source in the medium has been used up). The principal component analysis (PCA) showed distinct gene expression profile between control strain and L-UBB⁺¹ strain (Figure 1A and Supplementary Figure 1). Pair-wise comparisons of L-UBB⁺¹ strain and control strain revealed that 2212 and 2350 genes were significantly differentially expressed (adj-*P* < 0.001 and log₂FC \leq -1 or log₂FC \geq 1) during EX

and D6, respectively (Figure 1B and 1C). 1913 genes (72.2%) were significantly changed during both EX and D6 phases.

To gain more insight into biological processes affected by L-UBB⁺¹ expression, we also performed the gene set enrichment analysis (GSA) on the significantly differentially expressed genes. In the L-UBB⁺¹ strain, 23 and 29 gene sets were significantly upregulated and downregulated, respectively, in EX and D6 phases, compared to the control strain ($\text{adj-}P < 0.05$, Figure 1D). Gene sets associated with autophagy and

ubiquitin-related processes, such as “protein ubiquitination”, “ubiquitin-dependent protein catabolism”, “SCF-dependent proteasomal protein catabolism” and “ubiquitin-protein transferase activity”, were enriched among upregulated genes in the L-UBB⁺¹ strain. Our previous study showed the L-UBB⁺¹ expression inhibits proteolytic activities of 20S proteasome [27]. The inhibition of proteasome results in the compensatory activation of UPS and autophagy [31], which is in accordance with our genome-wide transcriptional analysis results. Gene sets related to transcription, such as “DNA-templated transcription”,




Figure 1. The global transcriptional response to constitutively low UBB⁺¹ expression. (A) Principal Component Analysis (PCA) of the normalized microarray data. (B–C) Volcano plot of log₂(FC) (Fold change) vs adjusted *p* value of differentially expressed genes comparing L-UBB⁺¹ strain and control strain during EX (B) and D6 (C). The dashed vertical grey line indicates the threshold of log₂(FC) (≤ -1 or ≥ 1), while the horizontal grey line indicates statistical significance threshold of adjusted *p* value < 0.05 . (D) The significantly enriched GO terms in L-UBB⁺¹ strain compared to control strain during EX and D6 phases. The red color indicates upregulated processes and blue color indicates downregulated processes. Samples are biological duplicates.

“transcription by RNA polymerase II”, “positive regulation of transcription by RNA polymerase II”, were enriched among upregulated genes as well (adj-*P* < 0.05, Figure 1D and Supplementary Figures 2 and 3). Whereas gene sets related to protein synthesis pathways, such as “translation”, “protein glycosylation”, “GPI anchor biosynthetic process”, “ER to Golgi transport”, “translocation”, were enriched among downregulated genes in the L-UBB⁺¹ strain (adj-*P* < 0.05, Figure 1D and Supplementary Figures 2 and 3), which may alleviate the ER stress by reducing the influx of newly synthesized proteins into ER. In addition to these protein syntheses and processing related processes, genes related to metabolic process, such as “lipid biosynthetic process”, “nucleotide biosynthetic processes” and “glycolytic process”, were significantly downregulated in the L-UBB⁺¹ strain (adj-*P* < 0.05, Figure 1D and Supplementary Figures 2 and 3).

Low expression of human UBB⁺¹ significantly increases the transcription of autophagy genes

Gene sets related to autophagy processes were significantly upregulated in the L-UBB⁺¹ strain (Figure 2 and Supplementary Table 1). Autophagy is a major catabolic pathway which critically secures eukaryotic cellular homeostasis and survival [32]. Activation of autophagy extends the lifespan of many other model systems such as the nematode *Caenorhabditis elegans* [33], fruit fly *Drosophila melanogaster* [34] and mice [35], and protects cells against a variety of stresses [36, 37]. Macroautophagy is the most prevalent form of autophagy in which double-membrane structures called the autophagosomes are formed around cargoes designated for degradation, such as aberrant organelles and misfolded/aggregated proteins [38]. It starts with the appearance of an isolated membrane termed the pre-autophagosomal structure [39], which expands and seals itself into an autophagosome while engulfing bulk portions of cytoplasm. Upon fusion with the vacuole, the inner autophagosome contents are degraded by lysosomal hydrolases (Figure 2A). About 35 autophagy-related genes (ATG) have been identified in yeast [40]. Among these, 18 ATG genes in six functional groups are required for autophagosome formation: the Atg1 complex, Atg9, the autophagy-specific phosphatidylinositol 3-kinase (PI3K) complex, the Atg2-Atg18 complex, and the Atg8 and Atg12 conjugation systems [41]. Compared to the control strain, 15 out of these 18 ATG genes were found significantly upregulated in the L-UBB⁺¹ strain (adj-*P* < 0.05, Figure 2B). The expression level of *ATG1*, an essential regulator required for the formation of the autophagosome in yeast [42], was 7.03 and 5.86-fold higher in the L-UBB⁺¹ strain during the EX phase and

D6 phase, respectively (Supplementary Table 2). qPCR (quantitative PCR) analysis verified that the transcript level of *ATG1* was 7.33-fold higher in L-UBB⁺¹ strain during EX phase (*p* < 0.001, Supplementary Figure 4).

Most genes involved in “regulation of autophagy” and “cvt pathway”, “pexophagy”, “mitophagy” and “micronucleophagy” were also significantly upregulated in the L-UBB⁺¹ strain (Figure 2C). Higher transcription levels of 10 autophagy related genes were further verified by qPCR analysis (Supplementary Figure 5). For illustration, 81 differentially expressed genes involved in autophagy related processes are listed in Supplementary Table 2.

Low expression of human UBB⁺¹ activates autophagy

To investigate whether the expression of L-UBB⁺¹ led to an actual activation of the autophagy pathway, autophagy was monitored by measuring the cleavage of a GFP-Atg8 fusion protein. Atg8p is a protein essential for autophagy, which is transported to the vacuole for degradation during autophagy. The proteolysis of GFP-Atg8 releases an intact GFP, which can be detected and correlated with the autophagic rate [43]. The cleavage of GFP-Atg8 was assessed at mid EX phase in both control strain and L-UBB⁺¹ strain. No cleavage of GFP was observed in control strain. In contrast, 36% of free GFP was detected in the L-UBB⁺¹ strain, indicating the activation of autophagy (Figure 3A and 3E). Nitrogen starvation and rapamycin treatment are two known activators of autophagy [44], which resulted in 90% and 59% of free GFP cleavage in our control strain, respectively (Figure 3A and 3E). When we analyzed the GFP-Atg8 cleavage in autophagy deficient mutant (*atg1Δ*) background, no GFP-Atg8 cleavage was observed in the *atg1Δ*-L-UBB⁺¹ strain, similar to the results from nitrogen starvation and rapamycin treatment in *atg1Δ*-control strain (Figure 3B). This indicates that the Atg1p is involved in L-UBB⁺¹-induced activation of autophagy. Fluorescent microscopy was used to study the localization of GFP-Atg8p. Since GFP is relatively resistant to degradation, it accumulates in the vacuole as autophagy proceeds. In the L-UBB⁺¹ strain, 24.1% of cells showed diffused GFP fluorescence in the vacuole (Figure 3C and 3F), which was significantly higher than 6% in the control strain (Figure 3C and 3F). The nitrogen starvation and rapamycin treatments in control strain showed respectively 91.1% and 83.2% of cells with stronger GFP fluorescence inside the vacuoles (Figure 3C and 3F). In the *atg1Δ* mutant strain, the accumulation of GFP fluorescence in the vacuole was absent under the same treatments (Figure 3D and 3F), revealing the inability of mutant cells to activate autophagy.

Autophagy was also monitored by following the bulk transport of cytosolic contents to vacuole for degradation using a FM 4-64 dye [45]. In the absence of autophagy, only the vacuolar perimeter was stained with FM 4-64 (Figure 4A). Under autophagy-induced conditions, cells showed intravacuolar staining and multivesicular bodies. Nitrogen starvation and rapamycin treatment resulted in 94.1% and 81.2% of cells showing such intravacuolar staining, respectively (Figure 4A and 4C). For the L-UBB⁺ strain, 29% of the cell population showed intravacuolar staining (Figure 4A and 4C), which was significantly higher than the control strain ($p < 0.05$). In the *atg1Δ* mutant background, there was no significant intravacuolar staining neither with L-UBB⁺ expression, nor under nitrogen starvation and rapamycin treatment (Figure 4B and 4C).

Low expression of human UBB⁺ significantly extends chronological life span

Beyond its function in turn-over and renewal of cellular contents, autophagy plays a prominent role in the life

span of many model organisms. Multiple reports indicate that a plethora of nutritional, pharmacological, or genetic manipulations that increase life span often stimulate autophagy, whereas inhibition of autophagy is associated with accelerated aging [34, 46, 47]. To determine whether the L-UBB⁺ expression-induced autophagy led to alterations in life span, we performed CLS analyses to the control, L-UBB⁺, *atg1Δ* and *atg1Δ*_L-UBB⁺ strains. The number of surviving cells were determined by colony forming unit (CFU) counting (Figure 5A) and PI staining (Figure 5B). Compared to the control strain, the L-UBB⁺ strain displayed a significantly greater survival after 5 days and the CLS extended from 13 days to 15 days ($p < 0.01$, Figure 5A). However, this markedly extended life span was abrogated when *ATG1* was deleted and life span was shortened to 11 days in *atg1Δ*_L-UBB⁺ strain (Figure 5A). The source data for Figure 5A was provided in Supplementary Table 3. In accordance with this, the PI staining showed significantly decreased fractions of dead cells in L-UBB⁺ culture on day 6 and day 9 compared to the control strain ($p < 0.01$, Figure 5B). The fraction of dead cells was 32%




Figure 2. Low UBB⁺ expression activates autophagy at the transcript level. (A) Schematic overview of autophagosome formation. (B) Fold changes in the expression of ATG genes encoding for autophagosome formation. Abbreviation: PI3K, phosphatidylinositol 3-kinase. (C) Fold changes in the expression of genes encoding different modes of autophagy. All comparison is between L-UBB⁺ strain and control strain during EX and D6 phases (adj- $p < 0.05$).

lower in L-UBB⁺¹ strain than control strain at day 9 (Figure 5B).

Low expression of human UBB⁺¹ significantly reduces A β levels and cytotoxicity

In previous study, we developed yeast A β models that mimic the chronic cytotoxicity of the amyloid peptides [28]. The expression of two major A β peptides, A β 40 and A β 42, interferes with cellular metabolism and causes

different levels of ER stress which regulate cell fate [29]. Here we took advantage of these established A β models to investigate whether the L-UBB⁺¹ expression could affect the different A β toxic isoforms. Immunostaining confirmed the localization of A β in the ER/secretory compartment (Figure 6A and Supplementary Figure 6A). In the A β 42 expression strain, A β concentrated in small foci (Figure 6A), compared to a more disperse distribution in the A β 40 strain (Supplementary Figure 6A), as we discovered previously [28]. A β oligomers were detected in




Figure 3. Low UBB⁺¹ expression activates autophagy. (A–B) Western blot of GFP-Atg8p processing into free GFP. GAPDH was used as the loading control. (C–D) Translocation of GFP-Atg8p into yeast vacuole. Top panel: images from FLUO-GFP filter. Bottom panel: images from DIC filter. White arrow: GFP fluorescence inside vacuole. Scale bar = 5 μ m. (E) The ratio of free GFP to total GFP (uncleaved GFP-ATG8 + free GFP) under wild type background was calculated and presented based on (A). Data is shown as average values \pm SD from biological triplicates. (F) The percentage of cells with diffuse vacuolar GFP fluorescence was counted and represented based on (C–D). Above 200 cells were count per sample ($n = 3 \pm$ SD). The asterisk (*) indicates a statistically significant p -value of < 0.05 from untreated control strain.

the A β 42 strain (Figure 6B) when protein lysates were not subjected to boiling, which disrupts the oligomers. In the A β 40 strain, only monomer and dimer were observed in unboiled samples (Supplementary Figure 6B). This clearly illustrates the different capacity of both peptides to form aggregates. When L-UBB⁺¹ was co-expressed in the A β 42 and A β 40 strains, a significant reduction in the immunostaining fluorescence was observed in both A β 42 (Figure 6A) and A β 40 strains (Supplementary Figure 6A). L-UBB⁺¹ expression significantly decreased A β levels in the A β 42 strain ($p < 0.05$, Figure 6B and 6C) as determined by immunoblotting. The A β 40 strain was less sensitive to L-UBB⁺¹ expression, which led to a milder reduction of A β 40 levels ($p < 0.05$, Supplementary Figure 6B and 6C).

The reduced intracellular A β 42 and A β 40 levels might in part be due to enhanced autophagy upon L-UBB⁺¹ expression. In the *atg1Δ* mutant strain, L-UBB⁺¹ co-expression did not significantly alter A β levels in neither A β 42 strain (Figure 6) nor A β 40 strain

(Supplementary Figure 6), indicating that activated autophagy was important for reduced A β levels upon L-UBB⁺¹ expression.

The A β 42 strain displayed a 17% reduction of maximal specific growth rate, compared to the control strain, and a shortened CLS of 9 days compared to 13 days in the control strain (Figure 7A), in agreement with our previous observations [28]. L-UBB⁺¹ expression did not restore the decreased maximal specific growth rate of the A β 42 strain (data not shown), however it did significantly enhance the cell survival. The CLS was extended to 15 days in the A β 42_L-UBB⁺¹ strain compared to 9 days in the A β 42 strain (Figure 7A). Although the A β 40 strain did not show the notable differences in physiology from control strain [29], CLS was shortened to 11 days compared to 13 days in the control strain. L-UBB⁺¹ co-expression also led to an extended CLS in the A β 40 strain, which showed a similar viability pattern with the A β 42_L-UBB⁺¹ strain (Figure 7A).




Figure 4. Low UBB⁺¹ expression increases vacuolar activity. Images of vacuole staining with FM 4-64 under wild type background (A) and *atg1Δ* mutant background (B). Top panel: FM 4-64 fluorescence. Bottom panel: overlay of DIC and FM 4-64 fluorescence images. White arrows indicate cells with intravacuolar staining. Scale bar = 5 μ m. (C) Quantification of the percentage of cells containing intravacuolar staining in the indicated strains. The data are shown as average values \pm SD from three independent experiments, with more than 200 cells per experiment. The asterisk (*) indicates significant differences from the untreated control strain ($p < 0.05$).

The *atg1Δ* mutant strain showed a shorter CLS compared to the control strain (Figure 7B). Deficient expression of *ATG1* (Unc-51) has been shown to decrease the life span of *C. elegans* [48] and *D.melanogaster* [49]. Aβ42 and Aβ40 expression in an *atg1Δ* mutant background led to a similar and remarkably shorter CLS of 7 days (Figure 7B), indicating that absence of autophagy increases cellular susceptibility to Aβ toxicity. L-UBB⁺ co-expression with Aβ42 or Aβ40 in the *atg1Δ* background strain increased cell survival (Figure 7B), however the effect was not as strong as that of co-expression in the wild type background (Figure 7A). The CLS was extended to 11 days in both *atg1Δ*_Aβ42_L-UBB⁺ strain and *atg1Δ*_Aβ40_L-UBB⁺ strain, with lower survival compared to *atg1Δ* mutant strain. This suggests that the Aβ toxicity attenuation by low UBB⁺ expression is not solely determined by elevated autophagy, but probably involves a secondary mechanism. The source data for Figure 7 was provided in Supplementary Table 3.

DISCUSSION

Humanized yeast models have been constructed and used to investigate molecular mechanisms underlying several human neurodegenerative disorders, by expressing human proteins implicated (or suspected to play a relevant role) in these diseases and studying the effects on yeast cell physiology, fitness, and different molecular pathways [50, 51]. UBB⁺ has been found to accumulate in the brain of AD patients [52] and it is thus believed that it might contribute to the development of neuropathology of AD [53], thus a humanized yeast model by using heterologous expression of UBB⁺ in yeast, could provide insights

into its role(s) *in vivo*. We found that constitutive low levels of UBB⁺ expression increase the capacity to degrade misfolded proteins and prevent cells to accumulate reactive oxygen species [27]. Here, we investigated the potential molecular mechanisms behind these effects by using genome-wide transcriptional analyses to generate hypotheses, which we tested by using molecular and cell biology tests. We found that the autophagy pathway was significantly upregulated in L-UBB⁺ strain, which may therefore contribute to decreased intracellular Aβ42 and Aβ40 levels and attenuated Aβ-induced cytotoxicity.

Autophagy is an evolutionarily conserved catabolic pathway used to degrade misfolded or aggregated proteins, as well as damaged cellular organelles, and is an important neuroprotective mechanism [54–56]. Neurons and glia in the central nervous system (CNS) are highly specialized post-mitotic cells that need to continuously remove defective proteins and organelles [57]. Cellular and animal models have shown that autophagy pathways are involved in the regulation of neurogenesis, and if they are not functional lead to neuronal disorders. Deficient autophagy in microglia results in impaired synaptic refinement and social behavioral defects [58, 59].

Our transcriptional analyses revealed that low expression of UBB⁺ elevated the expression of genes involved in ubiquitin-related processes and autophagy pathways. Genes involved in macroautophagy and selective autophagy pathways were significantly upregulated (Figures 1 and 2). In addition, UBB⁺ expression increased the intravacuolar accumulation of FM4-64 stained vesicles after PMSF treatment,




Figure 5. Low UBB⁺ expression extends ATG1-dependent CLS. (A) Survival of the L-UBB⁺ strain during stationary phase under wild type background and *atg1Δ* mutant background. Viability was determined by CFU counting. (B) Percentages of dead cells are shown as the fraction of propidium iodine (PI) positive cells. The data are shown as mean ± SD from biological duplicates. **p* < 0.01.

indicating increased vacuolar activity (Figure 4). Analysis of distribution and cleavage of GFP-Atg8 showed that UBB^{+1} expression promoted the uptake of Atg8 into vacuole and the cleavage of free GFP from the GFP-Atg8 fusion (Figure 3). This process occurs during autophagy where GFP-Atg8 is engulfed by the completed autophagosomes and then degraded [60]. Similar effects were observed with two known strong activators of autophagy, nitrogen starvation and rapamycin treatment (Figures 3 and 4), suggesting that low UBB^{+1} expression increases autophagy activity, but moderately. Impaired autophagy with reduced capacity to eliminate pathogenic proteins has been reported in many neurodegenerative disorders such as AD and PD [61]. Autophagy lysosomes are increased in early stages of AD, whereas impaired clearance of autophagic vesicles, e.g., maturation and transport of

autophagosomes, and reduced lysosomal proteolysis, are observed in later stages of AD, which may contribute to A β accumulation [62, 63]. Activating autophagy by rapamycin treatment, an inhibitor of mTOR pathway, protects neuroblastoma cells from A β toxicity [64], reduces cerebral A β load and slows AD progression in a transgenic AD mouse model [65]. Our data showed that low UBB^{+1} expression reduced intracellular levels of A β 42 and A β 40 in the wild type background but not in the *atg1 Δ* mutant background (Figure 6 and Supplementary Figure 6), indicating that L- UBB^{+1} expression decreased A β levels as a function of autophagy activation. Activation of autophagy has been shown to protect cells against multiple forms of stress, including nutrient and growth factor deprivation, reactive oxygen species, endoplasmic reticulum stress, damaged organelles or protein aggregates [66]. We




Figure 6. Low UBB^{+1} expression reduces A β 42 levels in the humanized yeast AD model. (A) Immunostaining analysis of A β 42 localization and expression using the 6E10 A β specific antibody. Nuclei were stained blue by DAPI. Scale bar = 5 μ m. (B) Western blot analysis of A β 42 expression in unboiled cell lysates with 6E10 antibody. GAPDH was used as the loading control. (C) Relative A β 42 band intensity was normalized to GAPDH and compared to the untreated A β 42 strain. Results are reported as mean \pm SD of three independent experiments. * p < 0.05.

observed that the low UBB^{+1} expression prolonged CLS in A β strains during chronological aging. The increased cell survival was reverted in the *atg1Δ* mutant background, further supporting the notion that activation of autophagy is crucial in promoting cellular survival and protection against A β induced toxicity.

Besides the autophagy pathways, the genome-wide transcriptional analyses also revealed that many UPS-related processes were activated in response to low UBB^{+1} expression. The UPS is a key component of the PQC for maintaining the proper concentrations of many regulatory proteins and clearing damaged/misfolded proteins [67]. Several studies suggest that sustained proteasome activity correlated with longevity, as found in centenarians [68], immortal cells such as human Embryonic Stem Cells (hESCs) [69], long-lived animals such as the naked mole-rat [70] and the giant clam [71]. The correlation has been further supported by genetic approaches. A genetic gain-of-function screening in *D. melanogaster* shows that *rpn11*, encoding a subunit of the 19S regulatory particle (RP), extends the flies' life spans with suppression of accumulated ubiquitinated proteins during aging process [72]. Increased expression of *rpn6*, another subunit of the 19S RP, results in elevated proteasome activity, clearance of toxic PolyQ aggregated and increased longevity in *C. elegans* [73]. *Rpn4* is required to induce proteasome subunits under conditions of proteasome dysfunction [74] and elevated *rpn4* levels increase UPS capacity which enhances replicative lifespan and resistance to proteotoxic stress in yeast [75]. The expression levels of *rpn11*, *rpn6* and *rpn4* were significantly increased in the L- UBB^{+1} strain, which may additionally assist in reducing A β cytotoxicity.

UPS and autophagy are two major protein degradation systems in eukaryotic cells, which aim at maintaining proteostasis. Recent studies strongly suggest functional crosstalk and interplay between these two systems. Autophagy can be activated in response to genetic or pharmacological inhibition of UPS [76]. With impaired proteasome function, the aberrant protein aggregates form large inclusion body-like structures known as aggresomes [77], which are thought to promote autophagy-mediated degradation [39]. Compensatory autophagy was induced in response to a dysfunctional UPS in a *Drosophila* model of the spinobulbar muscular atrophy via a histone deacetylase 6 (HDAC6)-dependent aggresome pathway [78]. The molecular mechanisms underlying autophagy activation in response to UPS inhibition are not clear, but many factors may be involved, including the N-terminal arginylation of N-end rule pathway [79], the unfolded protein response [80], and the BCL family protein MCL1 (myeloid cell leukemia sequence 1) [81]. Previous studies have showed that UBB^{+1} is a dose-dependent inhibitor of UPS [20]. We found previously that the overexpression of UBB^{+1} indeed decreases the proteolytic activities of the proteasome [27].

Overall, our study shows that low UBB^{+1} expression significantly increased the autophagy activity and thus induced intracellular degradation of A β , which increased cell fitness and survival. Identifying how moderate induction of autophagy can significantly reduce A β accumulation and consequently reduce its cytotoxicity could be relevant for understanding better the molecular onset and progression of AD, as well as potential targets for pharmacological intervention.




Figure 7. Low UBB^{+1} expression reduces A β 42 and A β 40 toxicity. (A) Survival of the A β 42 and A β 40 strains during stationary phase without or with low UBB^{+1} expression under wild type background. (B) Survival of the A β 42 and A β 40 strains during stationary phase without or with low UBB^{+1} expression under *atg1Δ* mutant background. Viability was determined by CFU counting. The data are shown as mean \pm SD from biological duplicates.

MATERIALS AND METHODS

Strains and cultivation

The haploid laboratory strain *S. cerevisiae* CEN.PK113-11C (*MATa his3Δ1 ura3-52 MAL2-8c SUC2*) [82] was used as a reference strain in this study. The *atg1Δ* mutant strain was constructed by transforming the reference strain with a PCR amplified *KanMX* cassette (from the pUG6 plasmid [83]) including approximately 500 bp upstream sequence and 500 bp downstream sequence flanks homologous to the *ATG1* locus. The gene deletion was confirmed by PCR using primers outside the *ATG1* open reading frame (ORF) and inside the *KanMX* gene respectively. All primers used are listed in the Supplementary Table 4. The previously described p413 TEF-UBB⁺, p416 GPD-Kar2-Aβ42 and p416 GPD-Kar2-Aβ40 plasmids for constitutive expression of UBB⁺, Aβ42 and Aβ40 respectively [27, 28] were transformed into the reference strain and *atg1Δ* strain. The p413 TEF-EP plasmid [84] was transformed into the reference strain and *atg1Δ* strain to construct control strains. The pRS416 GFP-ATG8 expression plasmid containing the *GFP-Atg8* gene under the endogenous *ATG8* promoter was donated by Prof. Daniel Klionsky, University of Michigan [85] (<http://www.addgene.org/49425/>, RRID:Addgene 49425). All plasmids and yeast strains used in this study are summarized in Supplementary Table 5.

All yeast transformations were performed following a standard lithium acetate method and transformants were selected on synthetic dextrose (SD) medium without histidine for L-UBB⁺ strain (SD-His, Formedium, England), or without uracil for Aβ42 and Aβ40 strains (SD-Ura, Formedium, England), or without both histidine and uracil for L-UBB⁺ and Aβ42/Aβ40 co-expression strains (SD-His-Ura, Formedium, England). For cultivation, strains were grown in liquid SD medium with 20 g l⁻¹ glucose. Synthetic minimal medium without ammonium sulfate and amino acids (YNB (-N) medium, Formedium) containing 20 g l⁻¹ glucose was used for nitrogen starvation experiments.

Transcriptome

Biological duplicate cultures from the control strain and L-UBB⁺ strain were sampled during EX and D6 for microarray analysis. Cells were frozen immediately in liquid nitrogen for rapid quenching of mRNA turnover [86]. Cells were mechanically disrupted using a FastPrep homogenizer (MP Biomedicals, USA) and total RNA was extracted using the RNeasy Mini Kit (QIAGEN, Germany). Quality of total RNA was assessed using an RNA 6000 Nano LabChip Kit (Agilent Technologies,

USA) with an Agilent 2100 Bioanalyzer (Agilent Technologies, USA). The labeled RNA was generated using the GeneChip® 3' IVT Plus Reagent Kit (Affymetrix, USA), which was hybridized to GeneChip® Yeast Genome 2.0 Arrays (Affymetrix, USA). Staining and washing of the hybridized arrays were performed on the GeneChip® Fluidics Station 450 (Affymetrix, USA). Further microarrays were scanned in GeneChip® Scanner 7G (Affymetrix, USA). RNA labelling, array hybridization and scanning were performed by the Bioinformatics and Expression Analysis core facility at Karolinska Institute, Sweden. Microarray data are available at the Genome Expression Omnibus website (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) with the accession numbers GSE129688. The transcriptome data (CEL files) were analyzed using the R version 3.4.0 and the PIANO package (Platform for Integrative Analysis of Omics) with information from the Saccharomyces Genome Database (<https://www.yeastgenome.org/>) [87]. Gene set enrichment analysis (GSA) was performed to identify overrepresentation of functional annotation categories using the Database for Annotation, Visualization and Integrated Discovery (David, <https://david.ncifcrf.gov/>). The S288C yeast genome background was used to analyze the magnitude of fold enrichment. The differential gene expression (log₂-FC) and corresponding significance (adjusted *p*-value) were calculated by the Benjamini–Hochberg method. Heatmaps of significantly differentially expressed genes and gene sets were generated by pheatmap R package.

Immunoblotting

Protein extraction and western blotting were performed as described previously [28]. 5 OD_{600 nm} of cells were spun down at 4000 g for 5 min. Cell pellets were resuspended in 200 µl of lysis buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 2.5 mM EDTA, 1% Triton X-100 with Complete Mini Protease Inhibitor (Roche, Switzerland). 200 µl of glass beads (MP Biomedicals, USA) was added to the solution, then the cells were mechanically disrupted for 3 min on the FastPrep homogenizer (MP Biomedicals, USA) at 4°C. Afterwards, samples were centrifuged at 13 000 g for 15 min at 4°C, and the supernatant was collected as lysate. Protein concentrations in the lysate were measured using a BCA protein assay kit (Thermo Scientific, USA) and 50 µg of protein for each sample was loaded on a 4–12% Bis-Tris gel (Invitrogen, USA). Primary antibodies 6E10 (anti-Aβ residues 1–16, Covance, USA), anti-GFP (Roche, Switzerland), anti-Ub⁺ (Santa Cruz, USA) and anti-GAPDH (Santa Cruz, USA) were used for immunoblotting. Blots were developed using ECL Prime reagents (GE Healthcare, USA) and scanned by ChemiDoc MP Imaging System (BioRad, USA). Images were quantified with Image J.

GFP-Atg8 processing assay

S. cerevisiae strains harboring the pRS416 GFP-Atg8 expression plasmid were grown to mid exponential phase ($OD_{600\text{ nm}}$ 0.5–0.6) in SD-Ura-His medium. Cells were washed in PBS once and cultured in SD-Ura-His medium, YNB (-N) medium and SD-Ura-His medium with 0.2 μM rapamycin respectively for 4 h at 30°C. Following incubation, 5 $OD_{600\text{ nm}}$ of cells were harvested for western blot analysis using anti-GFP antibody (Roche, Switzerland) and anti-GAPDH antibody (Santa Cruz, USA). The rest of cells were observed by Leica AF 6000 inverted fluorescence microscopy (Leica DMI4000B, Germany) using the DIC and FLUO-GFP filters. Images were processed with the Leica Application Suite (LAS) software.

FM 4-64 staining

As a lipophilic styryl dye, FM 4-64 specifically stains the vacuolar membrane in yeast based on the method described by Journo D et al. in 2008 [45]. Yeast cells (control, L-UBB⁺, *atg1Δ*_control and *atg1Δ*_L-UBB⁺ strains) were cultured to mid exponential phase ($OD_{600\text{ nm}}$ 0.5–0.6) in SD-His medium. 5 $OD_{600\text{ nm}}$ units of cells were harvested and resuspended in 1 ml of YPD medium containing 4 μM of FM 4-64 dye (Invitrogen, USA). Cells were cultivated for 30 min at 30°C in the dark. Then cells were resuspended in 10 ml of YPD without FM 4-64 and incubated for 40 min at 30°C. After washing in 50 mM HEPES buffer (pH 7) twice, cells were resuspended in either SD-His medium or YNB (-N) medium containing 1 mM PMSF (Phenylmethylsulfonyl fluoride, Sigma Aldrich, USA) and 10 mM sodium citrate (pH 4.3). Rapamycin (MW 914.17, Cat no. R8781, Sigma Aldrich, USA) treatment was done in SD-His medium with a final concentration of 0.2 μM . After 4 h incubation at 30°C, cells were washed and resuspended in YNB (-N) medium containing 10 mM sodium citrate (pH 4.3) and visualized by Leica AF 6000 inverted fluorescence microscopy (Leica DMI4000B, Germany) using the DIC and FLUO-RFP filters. Images were processed with the Leica Application Suite (LAS) software and the numbers of cells with intravacuolar staining were quantified.

Chronological Life Span (CLS) assay

CLS was determined as described previously [88]. Yeast strains were inoculated into 5 ml of SD-Ura, SD-His or SD-Ura-His medium depending on the strain requirements and grown overnight. After 20 h, cells were diluted into 20 ml of fresh SD medium to an initial $OD_{600\text{ nm}}$ of 0.1. Cultures were grown under continuous shaking (200 rpm) at 30°C. After 48 h, maximal cell

densities were reached and therefore this time point was considered as day 1. Subsequently, cellular viability was estimated by a CFU assay every two days until day 15. Approximately 400 cells were plated onto SD plates and incubated at 30°C for 48 h. CFU was calculated as the number of colonies formed divided by the number of plated cells.

Propidium iodide staining

Cell death was measured by propidium iodide (PI, Thermo Fisher Scientific, USA) staining as previously described [28]. 0.5 $OD_{600\text{ nm}}$ of cells were taken at different time points (e.g., 1-, 3-, 6- and 9-days) during cultivation. Cells were washed once at 4000 g for 5 min with PBS and stained with 0.5 $\mu\text{g ml}^{-1}$ of PI for 20 min in the dark. 5000 cells were analyzed for each sample with Guava flow cytometer (Merck, Germany). Experiments were performed in biological triplicates.

Immunostaining

Strains were grown in SD-Ura or SD-His medium overnight at 30°C. Cultures were diluted into 20 ml of SD medium ($OD_{600\text{ nm}}$ 0.1) and grown to mid exponential phase ($OD_{600\text{ nm}}$ 0.5–0.6). Cells were spun down and fixed immediately with 5 ml of 4% formaldehyde, 50 mM KPO₄ (pH 6.5) and 1 mM MgCl₂ for 2 h. After fixation, cells were washed in 5 ml of PM (0.1 M KPO₄ pH 7.5 and 1 mM MgCl₂) and resuspended in PMST (0.1 M KPO₄ pH 7.5, 1 mM MgCl₂, 1 M Sorbitol and 0.1% Triton X-100) to a final $OD_{600\text{ nm}}$ of 10. 100 μl of cells were incubated with 0.6 μl of 2-mercaptoethanol and 1 mg ml^{-1} zymolyase (Zymo Research, USA) for 40 min at 37°C. Spheroplast suspension was added to a polylysine-coated cover glass. The cells were blocked in 0.5% BSA/PMST for 30 min at RT, and incubated with primary antibody (6E10, Covance, USA) overnight at 4°C. After rinsing 3 times with PMST, cells were incubated with secondary antibody (anti-mouse Alexa 488, Dako, Denmark) for 2 h at RT in the dark. Then cells were stained with 0.4 mg ml^{-1} DAPI (4',6-diamidino-2-phenylindole) for 5 min in the dark. Images were acquired using Leica AF 6000 fluorescence microscope (Leica DMI4000B, Germany), and processed with LAS software.

Real-time quantitative PCR (qPCR)

qPCR was performed as previously described [29]. 1 μg of total RNA was used for cDNA synthesis with the QuantiTect Reverse Transcription Kit (QIAGEN, Germany). 2 μl of synthesized cDNA was used as the template for qPCR reaction with a DyNAmo Flash SYBR Green qPCR kit (Thermo Fisher Scientific, USA). Threshold cycle (Ct) values were obtained and

the $\Delta\Delta C_t$ method was used to calculate the fold change in transcript levels. RNA levels were normalized to the housekeeping gene *ACT1*. The primer sets are listed in Supplementary Table 4.

Statistical analysis

Significance of differences between strains were determined as mean \pm SD using two-tailed student *t* tests. A *p*-value < 0.05 was considered statistically significant unless specified explicitly. All experiments were done in biological triplicates unless specified otherwise.

AUTHOR CONTRIBUTIONS

X.C. and D.P. conceived and designed the study. X.C. and A.J.M.A. Performed the microarray experiment and analyzed the data. X.C. carried out the additional experiments and analyzed the data. X.C. and D.P. wrote the paper. All authors were involved in interpretation, editing, and discussions.

ACKNOWLEDGMENTS

X.C. thanks Dr. Boyang Ji and Dr. Markus M.M. Bisschops for the valuable comments on the paper. We acknowledge the Bioinformatics and Expression Analysis core facility at Karolinska Institute for help with the microarray experiments.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest related to this study.

FUNDING

This work was funded by the Kristina Stenborg Foundation (C2012/1241), the Chalmers Foundation (C2007/778) and the Novo Nordisk Foundation center for Biosustainability (21210022).

REFERENCES

- Hartl FU, Hayer-Hartl M. Converging concepts of protein folding in vitro and in vivo. *Nat Struct Mol Biol*. 2009; 16:574–81.
<https://doi.org/10.1038/nsmb.1591>
PMID:19491934
- Dobson CM. Protein folding and misfolding. *Nature*. 2003; 426:884–90.
<https://doi.org/10.1038/nature02261>
PMID:14685248
- Carrell RW, Lomas DA. Conformational disease. *Lancet*. 1997; 350:134–38.
[https://doi.org/10.1016/S0140-6736\(97\)02073-4](https://doi.org/10.1016/S0140-6736(97)02073-4)
PMID:9228977
- Sawkar AR, D'Haese W, Kelly JW. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease. *Cell Mol Life Sci*. 2006; 63:1179–92.
<https://doi.org/10.1007/s00018-005-5437-0>
PMID:16568247
- Koulov AV, LaPointe P, Lu B, Razvi A, Coppinger J, Dong MQ, Matteson J, Laister R, Arrowsmith C, Yates JR 3rd, Balch WE. Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis. *Mol Biol Cell*. 2010; 21:871–84.
<https://doi.org/10.1091/mbc.E09-12-1017>
PMID:20089831
- Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. *Annu Rev Neurosci*. 2003; 26:267–98.
<https://doi.org/10.1146/annurev.neuro.26.010302.081142>
PMID:12704221
- Morimoto RI. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. *Genes Dev*. 2008; 22:1427–38.
<https://doi.org/10.1101/gad.1657108>
PMID:18519635
- Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. *Nature*. 2011; 475:324–32.
<https://doi.org/10.1038/nature10317>
PMID:21776078
- Schmidt M, Finley D. Regulation of proteasome activity in health and disease. *Biochim Biophys Acta*. 2014; 1843:13–25.
<https://doi.org/10.1016/j.bbamcr.2013.08.012>
PMID:23994620
- Braun RJ, Sommer C, Leibiger C, Gentier RJG, Dumit VI, Paduch K, Eisenberg T, Habernig L, Trausinger G, Magnes C, Pieber T, Sinner F, Dengjel J, et al. Accumulation of Basic Amino Acids at Mitochondria Dictates the Cytotoxicity of Aberrant Ubiquitin. *Cell Rep*. 2015; 10:1557–71.
<https://doi.org/10.1016/j.celrep.2015.02.009>
PMID:25753421
- Dennissen FJ, Kholod N, van Leeuwen FW. The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim? *Prog Neurobiol*. 2012; 96:190–207.
<https://doi.org/10.1016/j.pneurobio.2012.01.003>
PMID:22270043

12. van Den Hurk WH, Willems HJ, Bloemen M, Martens GJ. Novel frameshift mutations near short simple repeats. *J Biol Chem*. 2001; 276:11496–98.
<https://doi.org/10.1074/jbc.M011040200>
PMID:11139590
13. Dennissen FJ, Kholod N, Hermes DJ, Kemmerling N, Steinbusch HW, Dantuma NP, van Leeuwen FW. Mutant ubiquitin (UBB+1) associated with neurodegenerative disorders is hydrolyzed by ubiquitin C-terminal hydrolase L3 (UCH-L3). *FEBS Lett*. 2011; 585:2568–74.
<https://doi.org/10.1016/j.febslet.2011.06.037>
PMID:21762696
14. Lindsten K, de Vrij FM, Verhoef LG, Fischer DF, van Leeuwen FW, Hol EM, Masucci MG, Dantuma NP. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. *J Cell Biol*. 2002; 157:417–27.
<https://doi.org/10.1083/jcb.200111034>
PMID:11980917
15. Wyss-Coray T. Ageing, neurodegeneration and brain rejuvenation. *Nature*. 2016; 539:180–86.
<https://doi.org/10.1038/nature20411>
PMID:27830812
16. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med*. 2016; 8:595–608.
<https://doi.org/10.15252/emmm.201606210>
PMID:27025652
17. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, Köycü S, Ramdjielal RD, Salehi A, Martens GJ, Grosveld FG, Peter J, Burbach H, Hol EM. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. *Science*. 1998; 279:242–47.
<https://doi.org/10.1126/science.279.5348.242>
PMID:9422699
18. van Leeuwen FW, van Tijn P, Sonnemans MA, Hobo B, Mann DM, Van Broeckhoven C, Kumar-Singh S, Cras P, Leuba G, Savioz A, Maat-Schieman ML, Yamaguchi H, Kros JM, et al. Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies. *Neurology*. 2006 (Suppl 1); 66:S86–92.
<https://doi.org/10.1212/01.wnl.0000193882.46003.6d>
PMID:16432153
19. Fischer DF, De Vos RA, Van Dijk R, De Vrij FM, Proper EA, Sonnemans MA, Verhage MC, Sluijs JA, Hobo B, Zouambia M, Steur EN, Kamphorst W, Hol EM, Van Leeuwen FW. Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. *FASEB J*. 2003; 17:2014–24.
<https://doi.org/10.1096/fj.03-0205com>
PMID:14597671
20. van Tijn P, de Vrij FM, Schuurman KG, Dantuma NP, Fischer DF, van Leeuwen FW, Hol EM. Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease. *J Cell Sci*. 2007; 120:1615–23.
<https://doi.org/10.1242/jcs.03438>
PMID:17405812
21. Tan Z, Sun X, Hou FS, Oh HW, Hilgenberg LG, Hol EM, van Leeuwen FW, Smith MA, O'Dowd DK, Schreiber SS. Mutant ubiquitin found in Alzheimer's disease causes neuritic beading of mitochondria in association with neuronal degeneration. *Cell Death Differ*. 2007; 14:1721–32.
<https://doi.org/10.1038/sj.cdd.4402180>
PMID:17571083
22. De Vrij FM, Sluijs JA, Gregori L, Fischer DF, Hermens WT, Goldgaber D, Verhaagen J, Van Leeuwen FW, Hol EM. Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death. *FASEB J*. 2001; 15:2680–88.
<https://doi.org/10.1096/fj.01-0438com>
PMID:11726544
23. Hope AD, de Silva R, Fischer DF, Hol EM, van Leeuwen FW, Lees AJ. Alzheimer's associated variant ubiquitin causes inhibition of the 26S proteasome and chaperone expression. *J Neurochem*. 2003; 86:394–404.
<https://doi.org/10.1046/j.1471-4159.2003.01844.x>
PMID:12871580
24. Yim N, Ryu SW, Han EC, Yoon J, Choi K, Choi C. Mutant ubiquitin UBB+1 induces mitochondrial fusion by destabilizing mitochondrial fission-specific proteins and confers resistance to oxidative stress-induced cell death in astrocytic cells. *PLoS One*. 2014; 9:e99937.
<https://doi.org/10.1371/journal.pone.0099937>
PMID:24941066
25. Verheijen BM, Stevens JAA, Gentier RJG, van 't Hekke CD, van den Hove DLA, Hermes DJHP, Steinbusch HWM, Ruijter JM, Grimm MOW, Haupenthal VJ, Annaert W, Hartmann T, van Leeuwen FW. Paradoxical effects of mutant ubiquitin on Aβ plaque formation in an Alzheimer mouse model. *Neurobiol Aging*. 2018; 72:62–71.
<https://doi.org/10.1016/j.neurobiolaging.2018.08.011>
PMID:30216939
26. Khurana V, Lindquist S. Modelling neurodegeneration in *Saccharomyces cerevisiae*: why cook with baker's yeast? *Nat Rev Neurosci*. 2010; 11:436–49.
<https://doi.org/10.1038/nrn2809>
PMID:20424620

27. Muñoz-Arellano AJ, Chen X, Molt A, Meza E, Petranovic D. Different Expression Levels of Human Mutant Ubiquitin B⁺ (UBB⁺) Can Modify Chronological Lifespan or Stress Resistance of *Saccharomyces cerevisiae*. *Front Mol Neurosci*. 2018; 11:200.
<https://doi.org/10.3389/fnmol.2018.00200>
PMID: [29950972](https://pubmed.ncbi.nlm.nih.gov/29950972/)
28. Chen X, Petranovic D. Amyloid- β peptide-induced cytotoxicity and mitochondrial dysfunction in yeast. *FEMS Yeast Res*. 2015; 15:fov061.
<https://doi.org/10.1093/femsyr/fov061>
PMID: [26152713](https://pubmed.ncbi.nlm.nih.gov/26152713/)
29. Chen X, Bisschops MMM, Agarwal NR, Ji B, Shanmugavel KP, Petranovic D. Interplay of Energetics and ER Stress Exacerbates Alzheimer's Amyloid- β (A β) Toxicity in Yeast. *Front Mol Neurosci*. 2017; 10:232.
<https://doi.org/10.3389/fnmol.2017.00232>
PMID: [28798664](https://pubmed.ncbi.nlm.nih.gov/28798664/)
30. Chen X, Ji B, Hao X, Li X, Eisele F, Nyström T, Petranovic D. FMN reduces Amyloid- β toxicity in yeast by regulating redox status and cellular metabolism. *Nat Commun*. 2020; 11:867.
<https://doi.org/10.1038/s41467-020-14525-4>
PMID: [32054832](https://pubmed.ncbi.nlm.nih.gov/32054832/)
31. Ji CH, Kwon YT. Crosstalk and Interplay between the Ubiquitin-Proteasome System and Autophagy. *Mol Cells*. 2017; 40:441–49.
<https://doi.org/10.14348/molcells.2017.0115>
PMID: [28743182](https://pubmed.ncbi.nlm.nih.gov/28743182/)
32. Lahiri V, Hawkins WD, Klionsky DJ. Watch What You (Self-) Eat: Autophagic Mechanisms that Modulate Metabolism. *Cell Metab*. 2019; 29:803–26.
<https://doi.org/10.1016/j.cmet.2019.03.003>
PMID: [30943392](https://pubmed.ncbi.nlm.nih.gov/30943392/)
33. Kenyon CJ. The genetics of ageing. *Nature*. 2010; 464:504–12.
<https://doi.org/10.1038/nature08980>
PMID: [20336132](https://pubmed.ncbi.nlm.nih.gov/20336132/)
34. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge L. Mechanisms of life span extension by rapamycin in the fruit fly *Drosophila melanogaster*. *Cell Metab*. 2010; 11:35–46.
<https://doi.org/10.1016/j.cmet.2009.11.010>
PMID: [20074526](https://pubmed.ncbi.nlm.nih.gov/20074526/)
35. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature*. 2009; 460:392–95.
<https://doi.org/10.1038/nature08221>
PMID: [19587680](https://pubmed.ncbi.nlm.nih.gov/19587680/)
36. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. *Cell*. 2008; 132:27–42.
<https://doi.org/10.1016/j.cell.2007.12.018>
PMID: [18191218](https://pubmed.ncbi.nlm.nih.gov/18191218/)
37. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. *Nature*. 2008; 451:1069–75.
<https://doi.org/10.1038/nature06639>
PMID: [18305538](https://pubmed.ncbi.nlm.nih.gov/18305538/)
38. Feng Y, He D, Yao Z, Klionsky DJ. The machinery of macroautophagy. *Cell Res*. 2014; 24:24–41.
<https://doi.org/10.1038/cr.2013.168>
PMID: [24366339](https://pubmed.ncbi.nlm.nih.gov/24366339/)
39. Takalo M, Salminen A, Soininen H, Hiltunen M, Haapasalo A. Protein aggregation and degradation mechanisms in neurodegenerative diseases. *Am J Neurodegener Dis*. 2013; 2:1–14.
PMID: [23516262](https://pubmed.ncbi.nlm.nih.gov/23516262/)
40. Klionsky DJ, Cregg JM, Dunn WA Jr, Emr SD, Sakai Y, Sandoval IV, Sibirny A, Subramani S, Thumm M, Veenhuis M, Ohsumi Y. A unified nomenclature for yeast autophagy-related genes. *Dev Cell*. 2003; 5:539–45.
[https://doi.org/10.1016/s1534-5807\(03\)00296-x](https://doi.org/10.1016/s1534-5807(03)00296-x)
PMID: [14536056](https://pubmed.ncbi.nlm.nih.gov/14536056/)
41. Nishimura T, Tooze SA. Emerging roles of ATG proteins and membrane lipids in autophagosome formation. *Cell Discov*. 2020; 6:32.
<https://doi.org/10.1038/s41421-020-0161-3>
PMID: [32509328](https://pubmed.ncbi.nlm.nih.gov/32509328/)
42. Kamada Y, Funakoshi T, Shintani T, Nagano K, Ohsumi M, Ohsumi Y. Tor-mediated induction of autophagy via an Apg1 protein kinase complex. *J Cell Biol*. 2000; 150:1507–13.
<https://doi.org/10.1083/jcb.150.6.1507>
PMID: [10995454](https://pubmed.ncbi.nlm.nih.gov/10995454/)
43. Cheong H, Klionsky DJ. Biochemical methods to monitor autophagy-related processes in yeast. *Methods Enzymol*. 2008; 451:1–26.
[https://doi.org/10.1016/S0076-6879\(08\)03201-1](https://doi.org/10.1016/S0076-6879(08)03201-1)
PMID: [19185709](https://pubmed.ncbi.nlm.nih.gov/19185709/)
44. Kohda TA, Tanaka K, Konomi M, Sato M, Osumi M, Yamamoto M. Fission yeast autophagy induced by nitrogen starvation generates a nitrogen source that drives adaptation processes. *Genes Cells*. 2007; 12:155–70.
<https://doi.org/10.1111/j.1365-2443.2007.01041.x>
PMID: [17295836](https://pubmed.ncbi.nlm.nih.gov/17295836/)
45. Journo D, Winter G, Abeliovich H. Monitoring autophagy in yeast using FM 4-64 fluorescence. *Methods Enzymol*. 2008; 451:79–88.

[https://doi.org/10.1016/S0076-6879\(08\)03207-2](https://doi.org/10.1016/S0076-6879(08)03207-2)
PMID:19185715

46. Eisenberg T, Knauer H, Schauer A, Büttner S, Ruckenstein C, Carmona-Gutierrez D, Ring J, Schroeder S, Magnes C, Antonacci L, Fussi H, Deszcz L, Hartl R, et al. Induction of autophagy by spermidine promotes longevity. *Nat Cell Biol.* 2009; 11:1305–14.
<https://doi.org/10.1038/ncb1975>
PMID:19801973
47. Meléndez A, Tallóczy Z, Seaman M, Eskelinen EL, Hall DH, Levine B. Autophagy genes are essential for dauer development and life-span extension in *C. elegans*. *Science.* 2003; 301:1387–91.
<https://doi.org/10.1126/science.1087782>
PMID:12958363
48. Tóth ML, Sigmond T, Borsos E, Barna J, Erdélyi P, Takács-Vellai K, Orosz L, Kovács AL, Csikós G, Sass M, Vellai T. Longevity pathways converge on autophagy genes to regulate life span in *Caenorhabditis elegans*. *Autophagy.* 2008; 4:330–38.
<https://doi.org/10.4161/auto.5618>
PMID:18219227
49. Lee JH, Budanov AV, Park EJ, Birse R, Kim TE, Perkins GA, Ocorr K, Ellisman MH, Bodmer R, Bier E, Karin M. Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. *Science.* 2010; 327:1223–28.
<https://doi.org/10.1126/science.1182228>
PMID:20203043
50. Yang J, Hao X, Cao X, Liu B, Nyström T. Spatial sequestration and detoxification of Huntingtin by the ribosome quality control complex. *Elife.* 2016; 5:e11792.
<https://doi.org/10.7554/eLife.11792>
PMID:27033550
51. Nair S, Traini M, Dawes IW, Perrone GG. Genome-wide analysis of *Saccharomyces cerevisiae* identifies cellular processes affecting intracellular aggregation of Alzheimer's amyloid- β 42: importance of lipid homeostasis. *Mol Biol Cell.* 2014; 25:2235–49.
<https://doi.org/10.1091/mbc.E13-04-0216>
PMID:24870034
52. Gentier RJ, van Leeuwen FW. Misframed ubiquitin and impaired protein quality control: an early event in Alzheimer's disease. *Front Mol Neurosci.* 2015; 8:47.
<https://doi.org/10.3389/fnmol.2015.00047>
PMID:26388726
53. Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. *Am J Pathol.* 2012; 181:1426–35.
<https://doi.org/10.1016/j.ajpath.2012.06.033>
PMID:22867711
54. Bjørkøy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. *J Cell Biol.* 2005; 171:603–14.
<https://doi.org/10.1083/jcb.200507002>
PMID:16286508
55. Kirkin V, Lamark T, Sou YS, Bjørkøy G, Nunn JL, Bruun JA, Shvets E, McEwan DG, Clausen TH, Wild P, Bilusic I, Theurillat JP, Øvervatn A, et al. A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. *Mol Cell.* 2009; 33:505–16.
<https://doi.org/10.1016/j.molcel.2009.01.020>
PMID:19250911
56. Thellung S, Corsaro A, Nizzari M, Barbieri F, Florio T. Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity. *Int J Mol Sci.* 2019; 20:901.
<https://doi.org/10.3390/ijms20040901>
PMID:30791416
57. Levine B, Klionsky DJ. Autophagy wins the 2016 Nobel Prize in Physiology or Medicine: Breakthroughs in baker's yeast fuel advances in biomedical research. *Proc Natl Acad Sci U S A.* 2017; 114:201–05.
<https://doi.org/10.1073/pnas.1619876114>
PMID:28039434
58. Kim HJ, Cho MH, Shim WH, Kim JK, Jeon EY, Kim DH, Yoon SY. Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects. *Mol Psychiatry.* 2017; 22:1576–84.
<https://doi.org/10.1038/mp.2016.103>
PMID:27400854
59. Wu X, Fleming A, Ricketts T, Pavel M, Virgin H, Menzies FM, Rubinsztein DC. Autophagy regulates Notch degradation and modulates stem cell development and neurogenesis. *Nat Commun.* 2016; 7:10533.
<https://doi.org/10.1038/ncomms10533>
PMID:26837467
60. Nair U, Thumm M, Klionsky DJ, Krick R. GFP-Atg8 protease protection as a tool to monitor autophagosome biogenesis. *Autophagy.* 2011; 7:1546–50.
<https://doi.org/10.4161/auto.7.12.18424>
PMID:22108003
61. Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. *Nat Rev Mol Cell Biol.* 2018; 19:365–81.
<https://doi.org/10.1038/s41580-018-0001-6>
PMID:29626215
62. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, Cuervo AM. Extensive involvement of

- autophagy in Alzheimer disease: an immuno-electron microscopy study. *J Neuropathol Exp Neurol*. 2005; 64:113–22.
<https://doi.org/10.1093/jnen/64.2.113>
PMID:15751225
63. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. *J Neurosci*. 2008; 28:6926–37.
<https://doi.org/10.1523/JNEUROSCI.0800-08.2008>
PMID:18596167
 64. Hung SY, Huang WP, Liou HC, Fu WM. Autophagy protects neuron from Aβeta-induced cytotoxicity. *Autophagy*. 2009; 5:502–10.
<https://doi.org/10.4161/auto.5.4.8096>
PMID:19270530
 65. Spilman P, Podlitskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. *PLoS One*. 2010; 5:e9979.
<https://doi.org/10.1371/journal.pone.0009979>
PMID:20376313
 66. Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. *Mol Cell*. 2010; 40:280–93.
<https://doi.org/10.1016/j.molcel.2010.09.023>
PMID:20965422
 67. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. *Annu Rev Biochem*. 2009; 78:477–513.
<https://doi.org/10.1146/annurev.biochem.78.081507.101607>
PMID:19489727
 68. Chondrogianni N, Petropoulos I, Franceschi C, Friguier B, Gonos ES. Fibroblast cultures from healthy centenarians have an active proteasome. *Exp Gerontol*. 2000; 35:721–28.
[https://doi.org/10.1016/s0531-5565\(00\)00137-6](https://doi.org/10.1016/s0531-5565(00)00137-6)
PMID:11053662
 69. Vilchez D, Boyer L, Morantte I, Lutz M, Merkwirth C, Joyce D, Spencer B, Page L, Masliah E, Berggren WT, Gage FH, Dillin A. Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. *Nature*. 2012; 489:304–08.
<https://doi.org/10.1038/nature11468>
PMID:22972301
 70. Pérez VI, Buffenstein R, Masamsetti V, Leonard S, Salmon AB, Mele J, Andziak B, Yang T, Edrey Y, Friguier B, Ward W, Richardson A, Chaudhuri A. Protein stability and resistance to oxidative stress are determinants of longevity in the longest-living rodent, the naked mole-rat. *Proc Natl Acad Sci U S A*. 2009; 106:3059–64.
<https://doi.org/10.1073/pnas.0809620106>
PMID:19223593
 71. Ungvari Z, Csiszar A, Sosnowska D, Philipp EE, Campbell CM, McQuary PR, Chow TT, Coelho M, Didier ES, Gelino S, Holmbeck MA, Kim I, Levy E, et al. Testing predictions of the oxidative stress hypothesis of aging using a novel invertebrate model of longevity: the giant clam (*Tridacna derasa*). *J Gerontol A Biol Sci Med Sci*. 2013; 68:359–67.
<https://doi.org/10.1093/gerona/gls159>
PMID:22904097
 72. Tonoki A, Kuranaga E, Tomioka T, Hamazaki J, Murata S, Tanaka K, Miura M. Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process. *Mol Cell Biol*. 2009; 29:1095–106.
<https://doi.org/10.1128/MCB.01227-08>
PMID:19075009
 73. Vilchez D, Morantte I, Liu Z, Douglas PM, Merkwirth C, Rodrigues AP, Manning G, Dillin A. RPN-6 determines *C. elegans* longevity under proteotoxic stress conditions. *Nature*. 2012; 489:263–68.
<https://doi.org/10.1038/nature11315>
PMID:22922647
 74. Dohmen RJ, Willers I, Marques AJ. Biting the hand that feeds: Rpn4-dependent feedback regulation of proteasome function. *Biochim Biophys Acta*. 2007; 1773:1599–604.
<https://doi.org/10.1016/j.bbamcr.2007.05.015>
PMID:17604855
 75. Kruegel U, Robison B, Dange T, Kahlert G, Delaney JR, Kotireddy S, Tsuchiya M, Tsuchiyama S, Murakami CJ, Schleit J, Sutphin G, Carr D, Tar K, et al. Elevated proteasome capacity extends replicative lifespan in *Saccharomyces cerevisiae*. *PLoS Genet*. 2011; 7:e1002253.
<https://doi.org/10.1371/journal.pgen.1002253>
PMID:21931558
 76. Zheng Q, Su H, Tian Z, Wang X. Proteasome malfunction activates macroautophagy in the heart. *Am J Cardiovasc Dis*. 2011; 1:214–26.
PMID:22081794
 77. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. *Trends Cell Biol*. 2000; 10:524–30.
[https://doi.org/10.1016/s0962-8924\(00\)01852-3](https://doi.org/10.1016/s0962-8924(00)01852-3)
PMID:11121744
 78. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. *Nature*. 2007; 447:859–63.


<https://doi.org/10.1038/nature05853>

PMID:[17568747](#)


79. Cha-Molstad H, Sung KS, Hwang J, Kim KA, Yu JE, Yoo YD, Jang JM, Han DH, Molstad M, Kim JG, Lee YJ, Zakrzewska A, Kim SH, et al. Amino-terminal arginylation targets endoplasmic reticulum chaperone BiP for autophagy through p62 binding. *Nat Cell Biol.* 2015; 17:917–29.
<https://doi.org/10.1038/ncb3177>
PMID:[26075355](#)
80. Hetz C, Chevet E, Oakes SA. Proteostasis control by the unfolded protein response. *Nat Cell Biol.* 2015; 17:829–38.
<https://doi.org/10.1038/ncb3184>
PMID:[26123108](#)
81. Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, Fischer KM, Sussman MA, Miyamoto S, Gustafsson ÅB. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. *Genes Dev.* 2013; 27:1365–77.
<https://doi.org/10.1101/gad.215871.113>
PMID:[23788623](#)
82. Entian KD, Kötter P. 25 Yeast Genetic Strain and Plasmid Collections. In: Stansfield I, Stark MJR, eds. *Methods in Microbiology.* Academic Press. 2007; 36:629–66.
[https://doi.org/10.1016/S0580-9517\(06\)36025-4](https://doi.org/10.1016/S0580-9517(06)36025-4)
83. Gueldener U, Heinisch J, Koehler GJ, Voss D, Hegemann JH. A second set of loxP marker cassettes for Cre-mediated multiple gene knockouts in budding yeast. *Nucleic Acids Res.* 2002; 30:e23.
<https://doi.org/10.1093/nar/30.6.e23>
PMID:[11884642](#)
84. Mumberg D, Müller R, Funk M. Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. *Gene.* 1995; 156:119–22.
85. Guan J, Stromhaug PE, George MD, Habibzadegah-Tari P, Bevan A, Dunn WA Jr, Klionsky DJ. Cvt18/Gsa12 is required for cytoplasm-to-vacuole transport, pexophagy, and autophagy in *Saccharomyces cerevisiae* and *Pichia pastoris*. *Mol Biol Cell.* 2001; 12:3821–38.
<https://doi.org/10.1091/mbc.12.12.3821>
PMID:[11739783](#)
86. Piper MD, Daran-Lapujade P, Bro C, Regenber B, Knudsen S, Nielsen J, Pronk JT. Reproducibility of oligonucleotide microarray transcriptome analyses. An interlaboratory comparison using chemostat cultures of *Saccharomyces cerevisiae*. *J Biol Chem.* 2002; 277:37001–08.
<https://doi.org/10.1074/jbc.M204490200>
PMID:[12121991](#)
87. Väre L, Nielsen J, Nookaew I. Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods. *Nucleic Acids Res.* 2013; 41:4378–91.
<https://doi.org/10.1093/nar/gkt111>
PMID:[23444143](#)
88. Fabrizio P, Longo VD. The chronological life span of *Saccharomyces cerevisiae*. *Methods Mol Biol.* 2007; 371:89–95.
https://doi.org/10.1007/978-1-59745-361-5_8
PMID:[17634576](#)

SUPPLEMENTARY MATERIALS


Supplementary Figures




Supplementary Figure 1. Principal Component Analysis (PCA). Histogram of variance for each PC shows that the first PC captures the largest variance of dataset, which is 91.94%.




Supplementary Figure 2. The Heatmap of consensus scores of selected gene sets in L-UBB+1 strain comparing to control strain during EX phase. Consensus score is the mean rank given each gene set by different GSA runs. A low score (e.g., 1) is a gene set that is ranked high by most of GSA methods. Gene sets that received a median consensus rank <10 in at least one class from five classes (distinct-directional down, mixed-directional down, non-directional change, mix-directional up and distinct-directional up), are included in the heatmap. The ranking of gene set was shown by colors. Gene sets clustered at the upper part are showing patterns of mostly down-regulation whereas the gene sets in the lower part are showing patterns of mainly up-regulation. The scores are presented inside each cell of the heatmap.




Supplementary Figure 3. The Heatmap of consensus scores of selected gene sets in L-UBB+1 strain comparing to control strain during D6 phase.



Supplementary Figure 4. qPCR analysis of ATG1 mRNA expression in control strain and L-UBB+1 strain during EX phase. Nitrogen starvation was induced in YNB (-N) medium for 4 h after mid-EX phase. Results are normalized to ACT1 mRNA level in control strain and shown as average values \pm SD from biological triplicates. The asterisk (*) indicates significant difference compared to control strain ($p < 0.001$).



Supplementary Figure 5. The transcriptional response of autophagy related genes upon the L-UBB⁺¹ expression during EX and PD phases. Results are normalized to *ACT1* mRNA level in control strain and shown as the average values \pm SD from biological triplicates.



Supplementary Figure 6. Low UBB⁺¹ expression reduces Aβ40 levels in the humanized yeast AD model. (A) Immunostaining analysis of Aβ40 localization and expression using the 6E10 Aβ specific antibody. Nuclei were stained blue by DAPI. Scale bar = 5 μm. **(B)** Western blot analysis of Aβ40 expression in unboiled cell lysates with 6E10 antibody. GAPDH was used as the loading control. **(C)** Relative Aβ40 band intensity was normalized to GAPDH and compared to the untreated Aβ40 strain. Results are shown as average value ± SD of three independent experiments. **p* < 0.05.

Supplementary Tables

Supplementary Table 1. Overrepresentation of autophagy associated processes with up-regulated genes in L-UBB⁺¹ strain.

Category description	No. of genes in dataset (EX/D6)	No. of genes in category	Fold enrichment (EX/D6)	<i>p</i> -value (EX/D6)
Mitophagy (GO:0000422)	20/23	48	2.05/2.30	$1.71 \times 10^{-3}/8.77 \times 10^{-5}$
Late nucleophagy (GO:0044805)	11/13	20	2.7/3.12	$2.91 \times 10^{-3}/1.52 \times 10^{-4}$
Nucleophagy (GO:0034727)	18/22	46	1.92/2.29	$6.69 \times 10^{-3}/1.36 \times 10^{-4}$
Regulation of autophagy (KEGG:sce04140)	8/11	17	2.76/3.63	$1.61 \times 10^{-2}/1.72 \times 10^{-4}$
Positive regulation of macroautophagy (GO:0016239)	7/8	12	2.87/3.20	$2.09 \times 10^{-2}/4.96 \times 10^{-3}$
Autophagy (GO:0006914)	29/38	100	1.43/1.82	$4.02 \times 10^{-2}/1.39 \times 10^{-4}$

p-value < 0.05 was used as a cutoff.

Supplementary Table 2. Genes with significantly different expression in autophagy pathways (L-UBB⁺¹ strain vs control strain) adjusted *p*-value <0.05 was used to identify significance.

Systematic name	Standard name	fold change in EX	Adjusted <i>p</i> -value in EX	fold change in Day 6	Adjusted <i>p</i> -value in Day 6
YGL180W	ATG1	2.81	6.76E-06	2.56	9.56E-06
YLL042C	ATG10	0.68	2.03E-03	0.93	3.72E-04
YPR049C	ATG11	2.51	2.18E-06	2.29	2.62E-06
YBR217W	ATG12	1.28	7.76E-05	1.60	2.46E-05
YPR185W	ATG13	0.64	6.50E-04	0.84	1.42E-04
YCR068W	ATG15	1.55	7.40E-05	1.34	1.53E-04
YLR423C	ATG17	0.12	6.21E-01	0.66	2.30E-02
YFR021W	ATG18	-0.85	7.66E-04	-0.73	1.60E-03
YOL082W	ATG19	-2.65	6.84E-06	-1.63	6.21E-05
YNL242W	ATG2	0.84	2.74E-03	0.94	1.50E-03
YDL113C	ATG20	1.03	2.85E-04	1.49	3.84E-05
YLR431C	ATG23	1.06	2.41E-04	1.45	4.45E-05
YLR189C	ATG26	2.76	2.55E-06	2.86	2.20E-06
YJL178C	ATG27	-1.57	9.21E-05	-1.50	1.10E-04
YNR007C	ATG3	1.85	1.37E-05	2.32	5.42E-06
YDR022C	ATG31	0.73	3.32E-02	1.50	1.13E-03
YIL146C	ATG32	3.10	1.19E-06	3.26	8.45E-07
YLR356W	ATG33	0.13	7.64E-01	0.80	7.17E-02
YOL083W	ATG34	2.30	3.30E-04	3.06	6.93E-05
YJL185C	ATG36	1.46	9.96E-04	1.84	2.74E-04
YLR211C	ATG38	-0.50	3.27E-02	-0.30	1.60E-01
YLR312C	ATG39	4.15	1.36E-06	4.56	8.45E-07
YNL223W	ATG4	1.30	2.06E-05	1.49	1.10E-05
YOR152C	ATG40	2.06	1.06E-04	2.53	3.52E-05
YPL149W	ATG5	-1.00	4.08E-05	-0.70	2.65E-04
YPL120W	ATG6	0.15	3.26E-01	0.33	4.75E-02
YHR171W	ATG7	0.35	2.96E-01	0.75	4.67E-02
YBL078C	ATG8	2.14	6.55E-05	2.88	1.48E-05
YDL149W	ATG9	1.48	1.29E-04	2.09	2.14E-05

YJL095W	BCK1	0.42	3.54E-03	0.40	4.31E-03
YML077W	BET5	-1.20	1.84E-05	-1.04	3.49E-05
YDR022C	CIS1	0.73	3.32E-02	1.50	1.13E-03
YGL215W	CLG1	1.84	2.66E-05	1.38	1.08E-04
YBR109C	CMD1	-0.86	1.31E-02	-0.66	3.66E-02
YFL024C	EPL1	1.67	3.01E-05	1.32	9.73E-05
YOR244W	ESA1	2.03	6.59E-06	2.05	6.19E-06
YNL127W	FAR11	0.75	5.64E-04	0.64	1.35E-03
YGR163W	GTR2	0.19	1.23E-01	0.37	1.15E-02
YGR223C	HSV2	1.89	1.04E-05	2.21	5.53E-06
YPL250C	ICY2	-1.60	4.76E-04	-2.08	1.10E-04
YHR082C	KSP1	1.45	7.74E-06	1.37	9.32E-06
YKR007W	MEH1	0.72	3.39E-04	1.03	5.10E-05
YPL140C	MKK2	1.65	4.59E-06	1.69	3.99E-06
YGL124C	MON1	-0.60	9.36E-03	-0.58	1.07E-02
YMR004W	MVP1	0.68	3.33E-04	0.92	6.37E-05
YEL062W	NPR2	-0.55	6.86E-03	-0.78	1.17E-03
YHR195W	NVJ1	0.27	2.43E-01	0.66	1.60E-02
YNL289W	PCL1	-2.66	2.38E-05	-2.68	2.23E-05
YHR071W	PCL5	1.25	3.75E-03	1.11	6.53E-03
YPL154C	PEP4	-0.91	6.97E-03	-0.59	4.18E-02
YOL001W	PHO80	0.91	5.88E-05	1.04	2.82E-05
YPL031C	PHO85	-0.01	9.41E-01	0.33	3.20E-02
YDR435C	PPM1	0.52	3.15E-03	0.77	3.84E-04
YNL330C	RPD3	0.73	1.23E-03	0.69	1.60E-03
YBL103C	RTG3	0.66	6.03E-03	0.50	1.99E-02
YPL085W	SEC16	0.49	2.04E-03	0.46	2.72E-03
YBL050W	SEC17	1.08	4.36E-05	1.39	1.29E-05
YNL272C	SEC2	0.57	1.64E-03	0.59	1.42E-03
YFL005W	SEC4	0.28	4.12E-02	0.60	1.19E-03
YBL058W	SHP1	0.73	6.54E-04	0.93	1.72E-04
YLR079W	SIC1	0.70	5.67E-04	0.88	1.65E-04
YBR077C	SLM4	1.05	1.44E-04	1.39	3.25E-05
YJL036W	SNX4	1.41	1.89E-05	1.67	8.55E-06
YAR042W	SWH1	1.43	1.42E-04	1.40	1.49E-04
YJR066W	TOR1	0.55	2.66E-03	0.41	1.08E-02
YKL203C	TOR2	1.04	1.44E-04	0.86	3.77E-04
YKR042W	UTH1	0.84	9.09E-03	0.25	3.22E-01
YDL077C	VAM6	0.33	3.29E-02	0.35	2.71E-02
YOR043W	WHI2	0.64	1.00E-03	0.39	1.09E-02
YPL120W	VPS30	0.15	3.26E-01	0.33	4.75E-02
YLR396C	VPS33	-0.91	1.11E-04	-0.98	7.02E-05
YOL105C	WSC3	0.72	1.59E-03	0.37	3.11E-02
YFL004W	VTC2	0.55	8.50E-04	0.41	3.86E-03
YPL019C	VTC3	0.51	4.11E-02	0.61	2.08E-02
YLR312C	YLR312C	4.15	1.36E-06	4.56	8.45E-07
YOR019W	YOR019W	1.25	8.12E-04	1.40	4.32E-04
YOR152C	YOR152C	2.06	1.06E-04	2.53	3.52E-05

YFL038C	YPT1	0.44	3.33E-03	0.54	1.10E-03
YGL210W	YPT32	0.54	1.15E-03	0.71	2.60E-04
YML001W	YPT7	-1.18	6.56E-05	-0.87	3.15E-04
YHR030C	SLT2	-1.27	1.24E-05	-1.40	6.15E-06

Supplementary Table 3. Source data for Figures 5 and 7.

Figure 5A

Strain	Day 1	Day 3	Day 5	Day 7	Day 9	Day 11	Day 13	Day 15
control_1	343	306	329	249	75	24	13	24
control_2	306	345	369	244	46	21	10	10
LUBB+1-1	401	372	406	404	310	157	53	
LUBB+1-2	410	384	437	398	258	73	33	
atg1Δ_LUBB+1-1	453	365	327	237	77	19		
atg1Δ_LUBB+1-2	435	394	341	203	99	24		
atg1Δ_1	355	281	302	246	118	3		
atg1Δ_2	406	305	257	225	101	14		

Figure 7A

	Day 1	Day 3	Day 5	Day 7	Day 9	Day 11	Day 13	Day 15
control 1	343	306	329	249	75	24	13	
control 2	306	345	369	244	46	21	10	
Aβ42_1	393	313	94	39	7			
Aβ42_2	391	374	101	32	4			
Aβ40_1	458	348	278	110	40	7		
Aβ40_2	402	453	296	139	22	12		
Aβ42_LUBB+1_1	326	272	319	299	133	48	22	9
Aβ42_LUBB+1_2	290	268	266	214	132	42	29	10
Aβ40_LUBB+1_1	295	371	316	309	192	64	48	13
Aβ40_LUBB+1_2	315	347	389	290	156	67	25	23

Figure 7B

	Day 1	Day 3	Day 5	Day 7	Day 9	Day 11
atg1Δ_Control_1	355	281	302	246	118	3
atg1Δ_Control_2	406	305	257	225	101	14
atg1Δ_Aβ 42_1	441	451	241	5		
atg1Δ_Aβ 42_2	456	418	248	11		
atg1Δ_Aβ 40_1	476	504	165	2		
atg1Δ_Aβ 40_2	523	475	139	0		
atg1Δ_Aβ 40_LUBB+1_1	354	300	209	154	68	5
atg1Δ_Aβ 40_LUBB+1_2	334	263	235	183	55	8
atg1Δ_Aβ 42_LUBB+1_1	368	289	218	160	72	17
atg1Δ_Aβ 42_LUBB+1_2	364	242	196	136	53	5

Supplementary Table 4. Primer-sets used in this study.

Primer	Sequence (5'–3')	Description
Atg1_up_fw_1	ACCGCTCGGCTCTGATTTCTTAAACC	Amplification of upstream of <i>ATG1</i> from genomic DNA
Atg1_up_rev	CTGCAGCGTACGAAGCTTCAGTTTCTTAATTTCTCGTCTGGTG	
Atg1_down_fw	GTGATATCAGATCCACTAGTGCCGTGATGCATAATATGGTTTTC	Amplification of downstream of <i>ATG1</i> from genomic DNA
Atg1_down_rev	GGATCTAAGTTAATTGTCATGTCGG	
KanMX_fw	CACCAGACGAGAAATTAAGAACTGAAGCTTCGTACGCTGCAG	Amplification of <i>KanMX</i> from pUG6 plasmid [83]
KanMX_rev_1	GAAAACCATATTATGCATCACGGCCACTAGTGGATCTGATATCAC	
Atg1_up_fw_2	CGCATTACACAGCTGCTCCGGAC	Verification of <i>KanMX</i> replacement of <i>ATG1</i>
KanMX_rev_2	TCACCATGAGTGACGACTGA	
Atg1_fw	TTGAGAACAGGCGCAGTATG	qPCR primers for <i>ATG1</i>
Atg1_rev	AAGGATCATTTCCGAACGTG	
Actin_fw	GCCTTCTACGTTTCCATCCA	qPCR primers for <i>ACT1</i>
Actin_rev	GGCCAAATCGATTCTCAAAA	
ATG39_fw	GAGGGGTCGAAACTGAAGGA	qPCR primers for <i>ATG39</i>
ATG39_rev	AAACCTGCCAACACATCACC	
ATG32_fw	ACTGGGGAAGACAAAGGCTT	qPCR primers for <i>ATG32</i>
ATG32_rev	ATGAAAGAAGCGCCCAAGTC	
ATG26_fw	AAATTCCGCTGCCAACATT	qPCR primers for <i>ATG26</i>
ATG26_rev	TTTGACCTGACTACCGGACC	
ATG11_fw	GCAGACGTAGATCTTTCGCG	qPCR primers for <i>ATG11</i>
ATG11_rev	TGTGAGCAAACGGTTAAGCC	
ATG34_fw	ATGGGACCGCATGAGATAGG	qPCR primers for <i>ATG34</i>
ATG34_rev	GTGTGGAAACTGCCTGTCTG	
ATG40_fw	AGACCCTTTGTAACGGAGCA	qPCR primers for <i>ATG40</i>
ATG40_rev	TCATTCGGGAAGTCAAGTCT	
ESA1_fw	CCGCGGATGGTTACAATGTT	qPCR primers for <i>ESA1</i>
ESA1_rev	AGCGTTATGAGAGTGTCGA	
HSV2_fw	GCAAACATCTCCAGTCGCAA	qPCR primers for <i>HSV2</i>
HSV2_rev	TGATGGAAGTGGGCAAAAGC	
CLG1_fw	AAGGTTCCGGCTACTTCTGCT	qPCR primers for <i>CLG1</i>
CLG1_rev	GGAAGGATAGGTGGTTGCT	
ATG36_fw	GGTGTGTTGGGCAGCCATTTA	qPCR primers for <i>ATG36</i>
ATG36_rev	TGTCAATAATTGCCGGCGAG	

Supplementary Table 5. Plasmids and *Saccharomyces cerevisiae* strains used in this study.

Name	Characteristics	References
Plasmid	Characteristics	
p413 TEF	CEN, <i>TEF1</i> promoter, <i>HIS3</i> marker	[84]
p413 TEF-UBB ⁺	p413TEF with UBB ⁺ sequence	[27]
p416 GPD	CEN, <i>GPD1</i> promoter, <i>URA3</i> marker	[84]
p416 GPD-Kar2-Aβ42	p416GPD with Kar2 and Aβ42 sequences	[28]
p416 GPD-Kar2-Aβ40	p416GPD with Kar2 and Aβ40 sequences	[28]
pRS416 GFP-Atg8	pRS416 with GFP and Atg8 sequences	[85]
Strain	Relevant genotype	
CEN.PK 113-11C	<i>MATa his3Δ1 ura3-52 MAL2-8c SUC2</i>	[82]
Control	CEN.PK 113-11C/p413 TEF	
L-UBB ⁺	CEN.PK 113-11C/p413 TEF-UBB ⁺	
Aβ42	CEN.PK 113-11C/p416 GPD-Kar2-Aβ42	[28]
Aβ40	CEN.PK 113-11C/p416 GPD-Kar2-Aβ40	[28]

Aβ42_L-UBB ⁺¹	CEN.PK 113-11C/p416 GPD-Kar2-Aβ42/p413 TEF-UBB ⁺¹	This study
Aβ40_L-UBB ⁺¹	CEN.PK 113-11C/p416 GPD-Kar2-Aβ40/p413 TEF-UBB ⁺¹	This study
GFP_Atg8	CEN.PK 113-11C/p413 TEF / pRS416 GFP-Atg8	This study
L-UBB ⁺¹ _GFP_Atg8	CEN.PK 113-11C/p413 TEF-UBB ⁺¹ /pRS416 GFP-Atg8	This study
<i>atg1Δ</i>	CEN.PK 113-11C/ <i>atg1::loxP</i> -KanMX4- <i>loxP</i>	This study
<i>atg1Δ</i> _Control	<i>atg1Δ</i> /p413 TEF	This study
<i>atg1Δ</i> _L-UBB ⁺¹	<i>atg1Δ</i> /p413 TEF-UBB ⁺¹	This study
<i>atg1Δ</i> _Aβ42	<i>atg1Δ</i> /p416 GPD-Kar2-Aβ42	This study
<i>atg1Δ</i> _Aβ40	<i>atg1Δ</i> /p416 GPD-Kar2-Aβ40	This study
<i>atg1Δ</i> _Aβ42_L-UBB ⁺¹	<i>atg1Δ</i> /p416 GPD-Kar2-Aβ42/p413 TEF-UBB ⁺¹	This study
<i>atg1Δ</i> _Aβ40_L-UBB ⁺¹	<i>atg1Δ</i> /p416 GPD-Kar2-Aβ40/p413 TEF-UBB ⁺¹	This study
<i>atg1Δ</i> _GFP_Atg8	<i>atg1Δ</i> /pRS416 GFP-Atg8/p413 TEF	This study
<i>atg1Δ</i> _GFP_Atg8_L-UBB ⁺¹	<i>atg1Δ</i> /pRS416 GFP-Atg8/p413 TEF-UBB ⁺¹	This study
